Abstract
We have performed genetic correlation and Mendelian randomization analyses using publicly available genome-wide association study (GWAS) data to identify endometrial cancer risk factors. These and previously established risk factors of endometrial cancer were then included in a multi-trait Bayesian GWAS analysis to detect endometrial cancer susceptibility variants, identifying three novel loci (7q22.1, 8q24.3 and 16q12.2); two of which were replicated in an independent endometrial cancer GWAS dataset. These loci are hypothesized to affect endometrial cancer risk through altered sex-hormone levels or through effects on obesity. Consistent with this hypothesis, several genes with established roles in these pathways (CYP11B1, CYP3A7, IRX3 and IRX5) were prioritized as candidate endometrial cancer risk genes by interrogation of quantitative trait loci data and chromatin capture assays in endometrial cell lines. The findings of this study identify additional opportunities for hormone treatment and further support weight loss to reduce the risk of developing endometrial cancer.
Statement of Significance This study prioritizes four genes related to testosterone and obesity as candidate endometrial cancer risk genes, as well as identifies additional opportunities for hormone treatment and further supports weight loss to reduce endometrial cancer risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a National Health and Medical Research Council (NHMRC) of Australia Investigator Grant (APP1173170) and a Cancer Australia PdCCRS Project Grant, funded by Cure Cancer Australia and the CanToo Foundation (#1138084) awarded to T.A.OM, as well as an NHMRC Project Grant (APP1158083) awarded to T.A.OM and D.M.G. T.A.OM and A.B.S. are supported by NHMRC Investigator Fellowships (APP1173170 and APP1177524). P.F.K. is supported by an Australian Government Research Training Program PhD Scholarship and QIMR Berghofer Postgraduate Top-Up Scholarship. E.J.C. is supported by a National Institute for Health Research (NIHR) Advanced Fellowship (NIHR300650). E.J.C., C.B. and D.G.E. were supported by the NIHR Manchester Biomedical Research Centre (IS-BRC-1215-20007).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial Support: This work was supported by a National Health and Medical Research Council (NHMRC) of Australia Investigator Grant (APP1173170) and a Cancer Australia PdCCRS Project Grant, funded by Cure Cancer Australia and the CanToo Foundation (#1138084) awarded to T.A.O’M, as well as an NHMRC Project Grant (APP1158083) awarded to T.A.O’M and D.M.G. T.A.O’M and A.B.S. are supported by NHMRC Investigator Fellowships (APP1173170 and APP1177524). P.F.K. is supported by an Australian Government Research Training Program PhD Scholarship and QIMR Berghofer Postgraduate Top-Up Scholarship. E.J.C. is supported by a National Institute for Health Research (NIHR) Advanced Fellowship (NIHR300650). E.J.C., C.B. and D.G.E. were supported by the NIHR Manchester Biomedical Research Centre (IS-BRC-1215-20007).
Conflict of Interest Statement: The authors declare no competing financial interests.
Data Availability
Summary-level GWAS results for endometrial cancer used that support the findings of this study are available from the NHGRI-EBI GWAS Catalog (https://www.ebi.ac.uk/gwas/downloads/summary-statistics), the Japanese Biobank (http://jenger.riken.jp/en/) and FinnGen (http://r2.finngen.fi/). The UK Biobank data used to perform GWAS of endometrial cancer risk was accessed via application number 25331. Summary-level GWAS results for all other traits used in this study can be downloaded from URLs provided in Supplementary Table S1. Other data generated or used during this study are included in this article and its supplementary information files or are available on reasonable request.
